Have a feature idea you'd love to see implemented? Let us know!

ANIK Anika Therapeutics Inc

Price (delayed)

$24.99

Market cap

$369.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.07

Enterprise value

$332.74M

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...

Highlights
Anika Therapeutics's debt has decreased by 7% YoY and by 2.1% QoQ
The company's gross profit rose by 4.6% YoY
Anika Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 4.5% from the previous quarter
ANIK's equity is down by 23% year-on-year

Key stats

What are the main financial stats of ANIK
Market
Shares outstanding
14.8M
Market cap
$369.77M
Enterprise value
$332.74M
Valuations
Price to book (P/B)
1.76
Price to sales (P/S)
2.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
Earnings
Revenue
$166.88M
EBIT
-$76.86M
EBITDA
-$63.51M
Free cash flow
$1.14M
Per share
EPS
-$5.07
Free cash flow per share
$0.08
Book value per share
$14.18
Revenue per share
$11.25
TBVPS
$16.94
Balance sheet
Total assets
$262.66M
Total liabilities
$52.32M
Debt
$25.79M
Equity
$210.34M
Working capital
$128.88M
Liquidity
Debt to equity
0.12
Current ratio
5.93
Quick ratio
3.7
Net debt/EBITDA
0.58
Margins
EBITDA margin
-38.1%
Gross margin
61.9%
Net margin
-44.4%
Operating margin
-45.8%
Efficiency
Return on assets
-26.4%
Return on equity
-32.9%
Return on invested capital
-42%
Return on capital employed
-32.5%
Return on sales
-46.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
-1.15%
1 week
1.75%
1 month
-0.75%
1 year
33.14%
YTD
10.28%
QTD
1.17%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$166.88M
Gross profit
$103.27M
Operating income
-$76.36M
Net income
-$74.18M
Gross margin
61.9%
Net margin
-44.4%
Anika Therapeutics's operating income has plunged by 167% YoY but it has increased by 4.7% from the previous quarter
Anika Therapeutics's operating margin has plunged by 159% YoY but it has increased by 3.4% from the previous quarter
The company's gross profit rose by 4.6% YoY
The net income rose by 3.5% since the previous quarter

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
1.76
P/S
2.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
The company's EPS rose by 3.4% QoQ
ANIK's equity is down by 23% year-on-year
ANIK's price to book (P/B) is 17% more than its last 4 quarters average of 1.5 and 3.5% more than its 5-year quarterly average of 1.7
ANIK's P/S is 33% below its 5-year quarterly average of 3.3 but 11% above its last 4 quarters average of 2.0
The revenue has grown by 2.9% YoY

Efficiency

How efficient is Anika Therapeutics business performance
The ROIC has dropped by 173% year-on-year but it is up by 4.5% since the previous quarter
The company's return on sales has shrunk by 166% YoY but it rose by 3.4% QoQ
Anika Therapeutics's ROE has decreased by 3.5% from the previous quarter
The return on assets has declined by 2.3% since the previous quarter

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
The total assets has decreased by 20% YoY
Anika Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 4.5% from the previous quarter
Anika Therapeutics's debt is 88% lower than its equity
ANIK's equity is down by 23% year-on-year
The debt to equity is up by 20% year-on-year but it is down by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.